Skip to content

Rubinstein-Taybi Syndrome: Functional Imaging and Therapeutic Trial

Rubinstein-Taybi Syndrome: Functional Imaging and Therapeutic Trial

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01619644
Acronym
RUBIVAL
Enrollment
41
Registered
2012-06-14
Start date
2012-04-01
Completion date
2014-09-01
Last updated
2026-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rubinstein-Taybi Syndrome

Keywords

RTS, Rubinstein Taybi, explorative phase 2, clinical approach, biological approach, motor skills

Brief summary

An exploratory phase 2 therapeutic trial in children from 6 to 21, RTS carriers, randomized to be treated either with sodium valproate with the usual pediatric dosage (30 mg/kg/j), or by placebo for one year. The investigator would like to include children because they could best profit from it due to their neuronal plasticity as CBP and EP300 take effect through neuronal and synaptic plasticity. The therapeutic effect of sodium valproate in RTS patients will be assessed thanks to a clinical approach (learning and memory neuropsychological evaluation, fine motor skills assessment by pointing), to a biological approach (histone acetylation functional tests), and to imaging (morphological and functional MRI).

Detailed description

Such a multidisciplinary approach has never been presented for this syndrome; it should enable us identifying specific cognitive and motor deficits and their association thanks to imaging markers. Assessing the various aspects of motor skills, i.e. primary (movements, standing at ease position, immobility) and complex motor skills (actions and behaviours, motor aspects of feelings and language expressions) is an integral part of the clinical examination in psychiatrics. The main interest of a functional capacity analysis is to be used as an index allowing the assessment of the nervous system's global capacities and the study of the connections between cognitive functions and motor skills Main objective: Evaluate long term memory with subtest "point location" - CMS and "image recognition" RBMT A patient is said to be responder if after one year his or her test result increase for one point at least one of the two tests : a increase of one point to "point location" or "image recognition". Double-blind phase 2 clinical trial, designed as a one-step Fleming design but with a control group. Rubival is a two-parallel group randomized trial: * a placebo group of 20 patients * a group of 40 patients taking sodium valproate (HDAC inhibitor) with an oral dosage of 30 mg/kg/jour

Interventions

DRUGsodium valproate

sodium valproate (HDAC inhibitor) with an oral dosage of 30 mg/kg/jour

DRUGPlacebo

Placebo with an oral dosage of 30 mg/kg/jour

Sponsors

University Hospital, Bordeaux
Lead SponsorOTHER
Fondation Syndrome de Rubinstein-Taybi
CollaboratorUNKNOWN

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
6 Years to 21 Years
Healthy volunteers
No

Inclusion criteria

* Children over 6 and under 21 * RTS confirmed by a genetic study with a CBP gene or EP300 gene mutation * Sufficient cognitive capacities for neuropsychological evaluation * Free and informed consent of the parents or guardians * Children affiliated to or benefiting of the French social welfare system

Exclusion criteria

* Contraindication to sodium valproate * Women of reproductive age without effective contraception means * Case history of sodium valproate treatment * Monotherapy treatment for epilepsy with Lamictal with a dosage superior to 5 mg/kg/j * Family history of severe hepatitis including drug * Acute or chronic hepatitis * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Memory tests (assessing memory learning)1 yearThe main outcome measure was to evaluate long term memory with two subtests : * point location, subtest of CMS (children memory scale). The score ranges from 0 to 6 * image recognition, subtest of RBMT (Rivermead Behavioural Memory Test). The score range from 0 to 10. One point for each image recognized A patient is said to be responder if after one year of treatment , his or her test result increase for one point at least one of the two tests

Secondary

MeasureTime frameDescription
Special brain imaging profile and motor skills (posturology and motor coordination in a visio-manual pointing task)1 yearFor motor skills, the profile was based on 3 tasks : posturology, motor coordination in a visuo-manual pointing task and in mobile interception task.. For brain imaging, a variety of outcome measures will be used for example, brain volume, anisotropy fraction, diffusion coefficient for structural magnetic imaging and the signal intensity for functional Magnetic Resonance Imaging
Cognitive and developmental profile1 yearBased on the results of several battery test and evaluation scale, VABS II (Vineland Adaptative Behaviour Scale II), Leiter R, EVIP, ECOSSE, NEPSY : fluency verbal sutest, CMS : 2 subtests, RBMT : 1 subtest
Histone acetylation profile1 year
Global acetylation level1 year
Acetylation level of selected gene1 year
Measurement of selected gene expression1 year

Countries

France

Contacts

PRINCIPAL_INVESTIGATORDidier LACOMBE, PU-PH

University Hospital Bordeaux, France

STUDY_CHAIRPaul PEREZ, PH

University Hospital Bordeaux, France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 15, 2026